Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial

• Published in: PLoS neglected tropical diseases Vol. 8; no. 3; p. e2739
• Main Authors: Klis, Sandor, Stienstra, Ymkje, Phillips, Richard O, Abass, Kabiru Mohammed, Tuah, Wilson, van der Werf, Tjip S
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.03.2014; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - adverse effects; Anti-Bacterial Agents - therapeutic use; Audiometry; Buruli ulcer; Buruli Ulcer - drug therapy; Child; Child, Preschool; Complications and side effects; Creatinine - blood; Dosage and administration; Drug dosages; Drug therapy; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Drugs; Family medical history; Female; Health aspects; Hearing loss; Hearing Loss - chemically induced; Hearing Loss - epidemiology; Hearing Loss - pathology; Humans; Kidney Diseases - chemically induced; Kidney Diseases - epidemiology; Kidney Diseases - pathology; Long term; Male; Medicine; Middle Aged; Mitochondrial DNA; Patient outcomes; Skin diseases; Streptomycin; Streptomycin - adverse effects; Streptomycin - therapeutic use; Studies; Surgery; Toxicity; Ulcers; Young Adult; Africa; Creatinine; Kidney Diseases; Streptomycin; Audiometry; Humans; Middle Aged; Child, Preschool; Male; Young Adult; Aged, 80 & over; Anti-Bacterial Agents; Drug-Related Side Effects & Adverse Reactions; Adolescent; Adult; Female; Aged; Buruli Ulcer; Child; Hearing Loss

Buruli Ulcer (BU) is a tropical infectious skin disease that is currently treated with 8 weeks of intramuscular streptomycin and oral rifampicin. As prolonged streptomycin administration can cause both oto- and nephrotoxicity, we evaluated its long term toxicity by following-up former BU patients th...